Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine
Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Sirona Dx, a technical contract research organization (CRO), providing advanced, single cell proteomics and genomics services to accelerate the pace of immunotherapy and targeted therapy development, announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and Biopharma.
Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology. “Our InSituPlex technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities offered by Sirona Dx. We believe this joint offering will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery and drug development process.” said Mark Rees, Ph.D. Vice President Corporate Development at Ultivue.
Sirona Dx are original pioneers of spatial biology, having launched ultra-high parameter, multiplexed imaging services to Biopharma in 2018. Their technology agnostic, full service, spatial biology suite, contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.
“We are delighted to announce this partnership with Ultivue” said Andrew Brown, Ph.D. Chief Commercial Officer at Sirona Dx. “Since 2018, clients have relied on our leading expertise to develop and implement customized, high performance multiplexed imaging panels of up to 40 markers. Having cast a wide net to identify the most informative tissue biomarker signatures, we can now harness Ultivue’s powerful InSituPlex® technology to rapidly develop, robustly validated mid-plex panels of up to 12 markers enabling our clients to accelerate their drug development programs with transformative biomarker capabilities.
About Sirona Dx
Sirona Dx is a technical CRO, founded to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between diagnostics manufacturers and translational clinical research our laboratory offers specialized high complexity, single cell proteomics and genomics services supporting pharmaceutical companies with their drug discovery and development programs. Learn more at Sironadx.com.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005096/en/
Contact information
Ultivue
Mark Rees, Ph.D.
Vice President Corporate Development
Mobile : (+1) 516-512-4977
ULTIVUE
USA: 763D Concord Ave. Cambridge, MA 02138-1044
Europe: Via Calabria, 15. 20090 Segrate. Milan. Italy
Website: www.ultivue.com
E. mail: mark.rees@ultivue.com
Sirona Dx
Andrew Brown, Ph.D.
Chief Commercial Officer
Mobile : (+1) 503-816-9692
SIRONA DX
USA: 4640 SW Macadam Ave, Suite 200 D, Portland, OR 97239
Website: www.sironadx.com
E. mail abrown@sironadx.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY – Digital Experience Is Recognised as No. 1 Internet Agency and Company Group for the Fourth Year in a Row by BVDW18.5.2022 09:30:00 CEST | Press release
As done in the previous three years, the Bundesverband Digitale Wirtschaft (BVDW) honours Reply – Digital Experience once again as the top company in their ranking of Internet Agencies for 2022. This recognition shows Reply – Digital Experience’s capability to offer technical solutions in conjuction with creative agency services and the right customer experience strategies. In addition, Reply – Digital Experience saw an increase in sales and their staff in the past financial year as a result of both continuous organic growth and the acquisition of Comwrap, a company headquartered in Frankfurt, specialised in cloud-based digital experience platforms. “To implement a holistic digital experience strategy it is essential to have the interplay of marketing and technology, outstanding creative ideas and a deep understanding of user needs. This involves the use of technology stacks and concepts such as artificial intelligence, virtual and augmented reality, data-driven marketing and conversat
Metanomic Acquires Intoolab, Developers of the First Bayesian Network Artificial Intelligence Engine18.5.2022 09:30:00 CEST | Press release
Today, Metanomic (https://www.metanomic.net/) announces it has acquired Intoolab A.I (https://www.intoolab.com/) , a Bayesian Network Artificial Intelligence company, to expand and to improve data analysis and A.I across video games and Web3. This acquisition augments Metanomic’s current game economy infrastructure that allows developers to build, simulate and run balanced game economies and core gameplay loops in a live, real-time environment. The addition of artificial intelligence helps developers create better experiences through intelligent insight from player behaviour in run-time. As a part of the acquisition the existing solution will be rebranded to Thunderstruck and extend the capabilities of the Metanomic Engine. A more intelligent approach to video game development and Web3 analytics Thunderstruck is based on a new approach to artificial intelligence that is not based on off the shelf machine learning algorithms but a powerful combination of Deep Learning and Dynamic Bayesi
Canadian Tire Bank Selects Temenos Open Platform to Gain Best-In-Class Digital Banking Capabilities18.5.2022 09:00:00 CEST | Press release
Temenos (SIX: TEMN) today announced that Canadian Tire Bank (CTB), the financial arm of Canadian Tire Corporation (CTC) – one of the largest Canadian retail companies – has selected Temenos open platform for composable banking to replace its legacy systems. Temenos will help power Canadian Tire Bank’s growth by delivering faster to market and richer digital experiences, boosting customer engagement and bottom-line revenue. The new banking platform is part of CTC’s Better Connected strategic growth plan to invest in its omnichannel customer experience. Temenos open platform will help Canadian Tire Bank (CTB) drive its digital-first strategy to enhance customer acquisition, loyalty and engagement. Canadian Tire Bank is one of the largest card issuers in Canada, with more than 2 million customers, over $6B in receivables and was recently ranked second in JD Power’s Canada Credit Card Satisfaction Study. With CTB focused on launching a new set of digital-only offerings, Temenos will help e
Temenos Delivers Digital Banking Solutions on AWS18.5.2022 08:30:00 CEST | Press release
Temenos (SIX: TEMN) and Amazon Web Services (AWS), have extended their global relationship to run Temenos onboarding and origination solutions on AWS. The technology collaboration aims to allow all retail and commercial banks - incumbents and challengers - to provide digital onboarding and origination solutions with higher performance, scalability, and security. It will give banks greater agility while reducing time to market and improve cost efficiency. The two companies will go-to-market with solutions for retail, business, corporate and private banking, and wealth. This multi-year agreement aims to offer the full suite of Temenos banking solutions on AWS as-a-service. Temenos and AWS started working together in 2019 to integrate Temenos open platform onto AWS and have demonstrated success with joint banking customers since then. With Temenos digital banking solutions, Temenos and AWS are making it easier for banks to access the technology they need to meet rising customer expectatio
Collecting Sensitive Data Without User Consent: 24 Leading Online Pharmacies From Nordic Countries Fail GDPR Requirements – Usercentrics Reports18.5.2022 08:01:00 CEST | Press release
Analysis by Usercentrics shows: Over 80% of scanned domains from Denmark, Sweden and Norway are not GDPR compliant, setting at least one non-necessary cookie without user consent. Sweden ranks highest with an average of 26 non-necessary cookies set. In total 89% of the most popular online pharmacies in the EU do not meet GDPR requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517006345/en/ Lack of Data Protection on EU Pharma Webshops: The majority of websites do not operate in a privacy-compliant manner - analysis by Usercentrics shows. (Graphic: Business Wire) Pharmacy webshops constantly process personal data of their visitors, while selling privacy-sensitive products such as antidepressants, diabetes medicines or addiction treatments. Usercentrics scanned the 150 most-used pharmacy webstores in the EU, analyzing the extent to which website operators are complying with the General Data Protection Regulation (